Lilly joins Novo in GLP-1 self-pay price cuts, lowering costs of single-dose Zepbound vials
On the heels of striking a deal with the Trump administration to reduce the prices of several of its most popular drugs for U.S. patients, Eli Lilly has unveiled additional savings for cash-paying users of its obesity and sleep apnea med Zepbound.
Espace publicitaire · 300×250